v3.10.0.1
Identifiable Intangible Assets and Goodwill - Goodwill (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Goodwill [Roll Forward]    
Beginning balance $ 55,952 [1] $ 54,449
Additions [2]   664
Other (2,541) [3] 840 [4]
Ending balance [1] 53,411 55,952
Innovative Health Segment [Member]    
Goodwill [Roll Forward]    
Beginning balance 31,141 30,134
Additions [2]   572
Other (2,264) [3] 435 [4]
Ending balance 28,877 31,141
Essential Health Segment [Member]    
Goodwill [Roll Forward]    
Beginning balance 24,811 24,315
Additions [2]   92
Other (277) [3] 404 [4]
Ending balance 24,534 24,811
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Consumer Healthcare [Member]    
Goodwill [Roll Forward]    
Goodwill $ 1,972 $ 0
[1] Amounts may not add due to rounding.
[2] IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A).
[3] Primarily reflects the impact of the reclassification of $2.0 billion to Assets held for sale during the fourth quarter of 2018 (see Note 2C), foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see Note 2B).
[4] Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.